SCHEMBL4773550

SCHEMBL4773550

CS(=O)(=O)N(Cc1cccc(C(F)(F)F)c1)c1ccc(N(C=O)Cc2ccc(C(F)(F)F)nc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 4/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC5 Q9UQL6 2/20 0.44
TRPM8 Q7Z2W7 5/20 0.42
SERPINE1 P05121 2/20 0.39
GRIN1 Q05586 2/20 0.37
GRIN2B Q13224 2/20 0.37
LMNA P02545 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
NAMPT P43490 1/20 0.36
NR3C1 P04150 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770892 0.90 LMNA (0.43) HDAC6HDAC1HDAC5TRPM8LMNA
SCHEMBL5571422 0.90 LMNA (0.40) HDAC6HDAC1HDAC5TRPM8LMNA
SCHEMBL4769798 0.88 GRM2 (0.44) GRIN1LMNANR3C1ALDH1A1
SCHEMBL4775014 0.86 TRPM8 (0.38) HDAC6HDAC1HDAC5TRPM8LMNA
SCHEMBL4767617 0.85 TRPM8 (0.40) HDAC6HDAC1HDAC5TRPM8
SCHEMBL4773593 0.85 CNR1 (0.36) HDAC6HDAC1HDAC5LMNAKMT2A
SCHEMBL4775075 0.84 CNR2 (0.37) TRPM8LMNAMEN1KMT2AALDH1A1
SCHEMBL4776872 0.83 RECQL (0.39) HDAC6HDAC1HDAC5LMNAALDH1A1
SCHEMBL4771247 0.83 ALDH1A1 (0.42) HDAC6TRPM8LMNAMEN1KMT2A
SCHEMBL4768261 0.83 TRPM8 (0.38) HDAC6TRPM8HDAC11NR3C1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 HDAC6 137/4885HDAC1 484/4885HDAC5 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.